FDA Launches TEMPO Digital Health Pilot to Accelerate Access to Chronic Disease Management Technologies
Key Insights
The FDA has launched the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program to evaluate a new enforcement approach for digital health devices targeting cardio-kidney-metabolic, musculoskeletal, and behavioral health conditions.
The pilot allows manufacturers to waive typical premarket authorization requirements while collecting real-world performance data through the CMS ACCESS payment program, which provides recurring payments for achieving measurable health outcomes.
Up to 40 U.S.-based manufacturers will be accepted across four therapeutic areas, with the program designed to demonstrate how digital health technologies perform in patients' everyday lives.
The US Food and Drug Administration has launched the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot, a groundbreaking initiative designed to accelerate safe access to digital health technologies for chronic disease management. The pilot, developed by the FDA's Center for Devices and Radiological Health (CDRH (search)), represents a significant shift in regulatory approach by allowing manufacturers to bypass traditional premarket authorization requirements while collecting real-world evidence.
Innovative Regulatory Framework
The TEMPO pilot evaluates a new enforcement approach specifically targeting digital health devices across four critical therapeutic areas: cardio-kidney-metabolic, musculoskeletal, and behavioral health conditions. These categories encompass conditions including high blood pressure, obesity, diabetes, and depression, addressing some of the most prevalent chronic diseases affecting Americans.
Manufacturers participating in the pilot will offer devices intended to provide care under the Centers for Medicare and Medicaid Services (CMS) Innovation Center's Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model. This integration allows companies to ask the FDA to waive premarket authorization and investigational device requirements while simultaneously collecting, monitoring, and reporting real-world performance data about their devices.
CMS ACCESS Program Integration
The CMS created the ACCESS program to address barriers to care stemming from Medicare's traditional fee-for-service payment model. Rather than paying for specific services, Medicare will make recurring payments to healthcare sites that manage patients' qualifying conditions. Sites will receive full payment if they achieve measurable health outcomes, creating a model designed to allow clinicians to adopt technology-supported care options.
This payment structure represents a fundamental shift toward value-based care, where healthcare providers are incentivized to achieve positive patient outcomes rather than simply deliver services. The integration with TEMPO creates a unique opportunity for digital health manufacturers to demonstrate real-world effectiveness while accessing Medicare reimbursement pathways.
Program Scope and Participation
The FDA plans to accept up to approximately 10 manufacturers based in the United States in each of the four therapeutic areas, totaling around 40 participants. Officials are actively seeking "manufacturers of all sizes, types and maturities," indicating an inclusive approach designed to foster innovation across the digital health ecosystem.
Applicants can utilize off-the-shelf technologies such as unregulated general-purpose computing platforms or wearables, lowering barriers to entry for companies developing innovative solutions. The FDA will evaluate whether digital health devices could pose serious risks to patient health, safety, or welfare, maintaining safety standards while streamlining access.
Strategic Vision and Impact
TEMPO was developed as part of the FDA's Home as a Health Care Hub initiative, which aims to relocate health and wellness services to the spaces where people live and work. This strategic vision recognizes the growing importance of remote and home-based healthcare delivery, particularly accelerated by the COVID-19 pandemic.
Michelle Tarver, CDRH (search) Director, emphasized the program's significance: "Digital health technologies are rapidly transforming how people manage chronic conditions, and we want to ensure our regulatory approach keeps pace. The TEMPO pilot will allow us to responsibly encourage innovation while collecting real-world evidence that may help us better understand how these devices perform for patients in their everyday lives."
Evidence-Based Development
The pilot builds on the CDRH (search)'s experience with the Total Product Life Cycle Advisory Program (TAP), which has demonstrated how early collaboration can streamline medical technology development. This experience informed TEMPO's focus on early engagement and extensive data collection, creating a framework for evidence-based regulatory decision-making.
Safe and effective digital technologies have the potential to greatly reduce the burden of chronic disease in the United States. The pilot will improve FDA and CMS understanding of how digital health technologies perform in real-world settings and how they could be applied to other chronic diseases in the future, potentially expanding the regulatory framework beyond the initial four therapeutic areas.